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Abstract
Background: Symptomatic or asymptomatic deep vein thrombosis (DVT) is a common 
complication following coronary artery bypass graft (CABG), in which less than 1% of these 
patients suffer from clinically evident pulmonary embolism (PE). DVT and PE can increase 
other morbidities of coronary revascularization from short to long period, but no clear consen-
sus still exists regarding proper thromboprophylaxis strategy in the literatures. This study was 
designed to compare the anti-platelet prophylaxis of aspirin plus heparin with heparin alone on 
asymptomatic perioperative DVT in patients that are candidates for elective off-pump CABG.
Methods: One hundred and twenty patients, who are candidates for elective off-pump CABG, were 
randomly assigned to two groups: the aspirin plus heparin group (Group 1, n = 60) that received  
80 mg daily aspirin orally and 5000 U unfractionated heparin per 8 h subcutaneously from 
admission to discharge time, and the heparin group (group 2, n = 60) that received same dose 
of heparin alone. All patients underwent right and left leg venous ultrasound examination 
during hospitalization, after which post-operative off-pump CABG complications such as deep 
vein thrombosis, bleeding and pulmonary embolism were evaluated in this study cases.
Results: The mean age of the patients was 62.10 ± 10.71 years with a male to female ratio  
of 2.24. Asymptomatic DVT occurred in 12 (10%) patients who underwent elective  
off-pump CABG. DVT was found more in Group 2 (16.6%) as compared to Group 1 (3.3%)  
with statistical significant difference (p = 0.015). Bleeding was detected in 5 (4.1%) cases in 
the patients sampled in this study (p = 0.34), 4 cases of which are from Group 1 and 1 case 
from Group 2. However, PE was shown in none of this study cases. 
Conclusions: The incidence of DVT decreased more with aspirin plus heparin as compared 
to heparin alone in patients who underwent elective off-pump CABG. As regards the results 
obtained in this study, more studies need to be conducted to establish this strategy for prophy-
laxis of DVT in CABG. (Cardiol J 2013; 20, 2: 139–143)
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Introduction
Coronary artery bypass graft (CABG) surge-
ry is the most common cardiac surgery [1] and 
deep vein thrombosis (DVT) is a common cause 
of morbidity and mortality following CABG. DVT 
was reported in 70–80% of patients who underwent 
open heart surgery, and can be asymptomatic [2–5]. 
Moreover, other morbidities which complicated the 
post-operative course immediately after DVT may 
cause complications for patients after they have 
been discharged from the hospital [2–5]. The ratio 
of upper limb to lower limb venous thrombosis 
was 6 fold [2–5]. Previous studies showed that 
predisposing factors for post-operative DVT are 
age, male sex, diabetes mellitus, hospitalization 
stay, cigarette smoking, hypercoagulophaty, fa-
miliar history of DVT and mechanical ventilation 
[6]. The incidence of post-operative DVT can be 
diminished with pharmacological prophylaxis. 
The common drugs for thromboprophylaxis are 
low molecular weight heparin (LMWH) and un-
fractionated heparin (UFH) [7–12]. Heparin can 
inhibit coagulation factors and fibrinolytic proteins 
but cannot affect primary hemostasis that occurs 
immediately after vessel constriction and platelet 
aggregation. Aspirin prevents the accumulation of 
platelet and inhibits primary hemostasis [7–12]. 
Previous trials indicated that preventing the scales 
of heparin alone on asymptomatic DVT was 60% 
to 70%, and preventing the scales of asprin alone 
was 40% to 50% [13, 14]. This study was designed 
to compare the antiplatelet prophylaxis of aspirin 
plus heparin with heparin alone on asymptomatic 
perioperative DVT in patients who underwent 
elective off-pump CABG.  
Methods
The prospective double blind randomized 
clinical trial performed in this study was approved 
by the ethics committee in our university. After 
receiving the written consent from patients, they 
participated voluntarily in off-pump CABG surgery 
from 14 August 2010 to 3 August 2011 in Afshar 
Cardiovascular Center, Yazd, Iran. All of the opera-
tions were performed by the one senior surgeon. 
The nurse (observer) who took the medicine to 
the patients (participants) and the patients them-
selves were blinded. Patients with a history of 
concomitant DVT, other cardiac surgery or planned 
anticoagulation (i.e., for atrial fibrillation or mecha-
nical prosthetic valves), symptomatic DVT, history 
of PTE and candidates for on-pump CABG were 
excluded. The patients were randomly assigned 
into two groups: the aspirin plus heparin group 
(Group 1, n = 60) which received 80 mg aspirin 
orally on a daily basis and 5000 U UFH per 8 h 
subcutaneously from admission to discharge time, 
and the heparin group (Group 2, n = 60) which 
received same dose of heparin alone. All patients 
underwent right and left leg venous ultrasound 
examination. Ultrasonography was performed by 
an experienced and expert physician using Acuson 
128 or Sequoia ultrasound systems equipped with 
4-MHz and 7.5-MHz transducers with duplex and 
color Doppler capability. Both legs including the 
calf veins were scanned from the groin distally. 
The common femoral, deep femoral, superficial 
femoral and popliteal veins were imaged. Imaging 
of the calf veins was obtained both transversely 
and longitudinally, and confirmed with color-flow 
accentuation after the lower third of the calf was 
squeezed. The demographic variables and pre-ope-
ration and post-operation hemoglobin, hematocrit, 
platelet, activated clotting time (ACT), activated 
partial thromboplastin time (aPTT), prothrombin 
time (PT) and post-operation early complications 
such as bleeding and pulmonary embolism (PE), 
were recorded. 
Statistical analysis
The individual who recorded the data did not 
know about the patients’ groups. The data obtained 
in this study were analyzed by SPSS 16.5 software. 
We used ANOVA, c2, Fisher exact test and T-test 
for quantitative and qualitative variables.
Results
One hundred and twenty patients with mean 
age of 62.10 ± 10.71, who are candidates for off-
-pump CABG surgery, enrolled in this study. Of 
these, 83 (69.16%) patients were males and 37 
(30.8%) patients were females. The demographic 
characteristics of the patients are presented in 
Table 1. Of all the participants, asymptomatic DVT 
was observed in 12 (10%) cases, 2 (3.3%) cases of 
which were from Group 1 and 10 (16.6%) cases 
were from Group 2 (p = 0.015). Of the 12 cases 
with asymptomatic DVT, 9 were males and 3 were 
females. There was no significant relationship be-
tween sex and DVT after surgery (p > 0.05). The 
patients were divided into two age groups: less 
than 50 years old (14 cases) and above 50 years old 
(106 cases). Post-CABG DVT occurred in 1 case in 
the less than 50 year-old group, whereas it occurred 
in 11 cases in the above 50 year-old group. There 
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was no statistical significant relationship between 
DVT and age (p = 0.18). The significant stenosis of 
1, 2, 3 and left main coronary artery (LMCA) disease 
alone, LMCA plus 3 vessels disease, LMCA plus 
single vessel disease in the patients, and the num-
ber of these patients with these involvements who 
suffered from DVT, are presented in Table 2. It was 
observed that no correlation was found between 
DVT and gender, diabetes mellitus, hypertension 
(HTN), hyperlipidemia (HLP), disability, cigarette 
smoking, history of utilization of oral contraceptive 
(OCP), severe heart failure, chronic obstructive 
pulmonary disease (COPD), and valvular heart 
disease (p > 0.05). There was no statistical signifi-
cant difference between the pre- and post-operative 
ACT, aPTT and PT of the two groups (p > 0.05). 
In the study patients, post-operative bleeding was 
observed in 4 (6.7%) cases in aspirin plus heparin 
group as compared to 1 (1.7%) case in heparin alone 
group. It was observed that there was no significant 
statistical differences between the post-operative 
bleeding of the two groups (p = 0.34). However, 
no cases were observed with pulmonary embolism 
in the patients during the post-operative period in 
both groups (Tables 3, 4).
Discussion
Venous thromboembolism (VTE), which con-
sists of DVT and PE, is a major cause of morbidity 
and mortality in patients undergoing open heart 
surgery [15, 16]. 
Without prophylactic anticoagulation, the 
frequency of DVT after cardiac surgery is high; 
however, with anticoagulation therapy, this inci-
dence can be reduced significantly. The results of 
this study are in agreement with those of previous 
studies [15, 16] which indicated a relatively high 
rate of DVT after CABG in most cases without 
clinically significant symptoms. Goldhaber et al. 
[17] reported an incidence of approximately 22% 
DVT post-CABG. Nevertheless, specific guideli-
nes for thromboprophylaxis after CABG surgery 
Table 1. Demographic characteristics of both groups.
Variables Heparin Hep + Asp P
Age [year] 63.41 ± 10.71 60.80 ± 10.64 0.18
Sex (male/female) 42/18 41/19 0.84
Hypertension 30 (50%) 27 (45%) 0.58
Diabetes mellitus 28 (46.7%) 17 (28.3%) 0.06
Cigarette smoking 16 (26.7%) 16 (26.7%) 1.000
Hyperlipidemia 19 (31.7%) 24 (40%) 0.34
Severe heart failure 1 (1.4%) 1 (1.7%) 0.9
Disability 2 (3.3%) 0 (0%) 0.49
Oral contraceptive drug 5 (14%) 17 (16%) 0.29
Valvular disease 18 (30%) 26 (43.3%) 0.13
Chronic obstructive pulmonary disease 4 (6.7%) 3 (5.0%) 0.09
Data presented as mean ± standard deviation; Hep + Asp — heparin+aspirin 
Table 2. Deep vein thrombosis in kinds of cardiac vessels involvements; p = 0.94. 
Cardiac vessels involvements Deep vein thrombosis No deep vein thrombosis 
Single vessel 1 (10%) 9 (90%)
Two vessels 2 (8.3%) 22 (91.7%)
Three vessels 9 (11.5%) 69 (88.5%)
Left main coronary artery (LMCA) 0 2 (100%)
LMCA + three vessels 0 5 (100%)
LMCA + single vessel 0 1 (100%)
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are not currently available. Thromboprophylaxis 
interventions after CABG surgery, according to 
early passive and active mobilization, are periodic 
pneumatic compression, the routine use of antipla-
telet therapy, and subcutaneous heparin in selected 
patients [18]. In patients who received heparin 
after cardiac surgery, prophylaxis may administer 
protection against VTE, especially in patients with 
ongoing risk factors. According to previous studies, 
the best choice for the efficacy of routine heparin 
prophylaxis in prevention of VTE after CABG is 
low molecular weight heparin, which is also cost 
effective [18].
The results of the meta-analysis performed by 
Mismetti et al. [19, 20] about the effect of LMWH 
on prevention of VTE indicated that LMWH can 
decrease this complication significantly. In a study 
conducted by Hovens et al. [21], aspirin was used as 
an antiplatelet as compared to placebo and it dimi-
nished thromboembolism significantly.
An animal study done by Chung et al. [22] 
reported that antiplatelet plus anticoagulation drug 
in rat model was more effective in the prevention 
of DVT to aspirin or heparin alone. This present 
study showed that administration of aspirin plus 
heparin in candidates of off-pump CABG surgery 
had more preventive effects on asymptomatic 
perioperative DVT than heparin alone. This stu-
dy indicated that incidence of DVT was 16.6% 
in heparin group as compared to 3.3% in aspirin 
plus heparin group; therefore, antiplatelet drug 
can be appropriated synergic effects with heparin 
on diminishing DVT. The results of this study are 
similar to those obtained by Chung in his study. 
In this present study, sex, diabetes mellitus, 
HTN, HLP, disability, cigarette smoking, history 
of utilization of OCP, severe heart failure, COPD, 
involved vessels and valvular heart disease, were 
not correlated with the incidence of asymptomatic 
DVT (p > 0.05). Also, it was found that bleeding 
had no statistical difference between the two 
groups (p = 0.34). 
Liau et al. [23] showed that surgical bleeding 
did not increase with the use of anticoagulation and 
antiplatelet agents for prevention of DVT. A study 
conducted by Sirvinskas et al. [24] reported that 
surgical bleeding in patients that received heparin 
was lower than those that received aspirin for the 
prevention of DVT. However, Veikutiene et al. [25] 
found that surgical bleeding in aspirin group was 
lower than that in heparin group. In this study, 
bleeding had no significant difference between 
the two groups. Also, it was observed that blood 
factors such as pre- and post-operation hemoglobin, 
hematocrit and platelet were similar in both groups.
A study carried out by Zibaeenezhad and 
Mazloum [26] reported that heparin infusion 
can significantly increase the occurrence of 
bleeding and vascular injury. In this present stu-
dy, no patients suffered from PE in both groups. In 
a study done by Ambrosetti et al. [27], it was re-
ported that PE following DVT was lower than one 
percent [27]. A possible limitation of this study 
could be the use of only a noninvasive imaging 
Table 4. Preoperation and postoperation blood factors in both group.
Variables Heparin Heparin + aspirin P
Hemoglobin (pre) 13.52 ± 1.32 13.54 ± 1.37 0.93
Hemoglobin (post) 12.7 ± 1.21 12.6 ± 1.46 0.95
Hematocrit (pre) 42.26 ± 4.34 42.01 ± 5.48 0.78
Hematocrit (post) 36.4 ± 3.88 36.13 ± 3.87 0.66
Platelet (pre) 242.6 ± 67.6 244.8 ± 64.6 0.83
Platelet (post) 214.3 ± 54.7 204.08 ± 57.8 0.32
Data presented as mean ± standard deviation
Table 3. Postoperation early complications in both groups. 
Variables Heparin Heparin + aspirin P
Deep vein thrombosis 10 (16.6%) 2 (3.3%) 0.015
Bleeding 1 (1.7%) 4 (6.7%) 0.34
Pulmonary embolism 0 (0%) 0 (0%) 1.000
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modality (ultrasonography) to detect DVT cases. 
Ultrasonography is used as a sensitive and specific 
diagnosis for proximal vein thrombosis such as 
thrombosis in the popliteal, femoral, and iliac veins 
in patients suspected of having a first episode of 
DVT [28, 29].
Conclusions
It can be concluded that aspirin plus hepa-
rin as compared to heparin alone, significantly 
reduced asymptomatic DVT following elective 
off-pump CABG and early post-operative com-
plications such as bleeding or PE which had no 
significant difference between the two groups. 
Our results need to more studies to establish 
this strategy for prophylaxis of DVT in CABG. 
Acknowledgements
This project is the result of medical thesis 
of Dr. Seyed Mohammad Yousof Mostafavi Pour 
Manshadi practicing as general practitioner.
Conflict of interest: none declared
References
 1.  Serruys PW, Morice MC, Kappetein P et al. Percutaneous co-
ronary intervention versus coronary-artery bypass grafting for 
severe coronary artery disease. N Engl J Med, 2009; 360: 
961–972.
 2.  Oger E. Incidence of venous thromboembolism: A community-
-based study in Western France. EPI-GETBP Study Group. 
Groupe d’Etude de la Thrombose de Bretagne Occidentale. 
Thromb Haemost, 2000; 83: 657–660.
 3.  Samama MM. An epidemiologic study of risk factors for deep 
vein thrombosis in medical outpatients: The Sirius study. Arch 
Intern Med, 2000; 160: 3415–3420.
 4.  Goldhaber SZ, Elliott CG. Acute pulmonary embolism, part I: 
Epidemiology, pathophysiology, and diagnosis. Circulation, 2003; 
108: 2726–2729.
 5.  Dalen JE. Pulmonary embolism: What have we learned since 
Virchow? Natural history, pathophysiology, and diagnosis. Chest, 
2002; 122: 1440–1456.
 6.  Holbrook A, Schulman S, Witt DM et al. American College of 
Chest Physicians. Evidence-based management of anticoagulant 
therapy: Antithrombotic Therapy and Prevention of Thrombosis, 
9th  Ed. American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines. Chest, 2012; 141 (2 suppl.): e152S– 
–e84S.
 7.  Paparella D, Galeone A, Venneri MT et al. Activation of the 
coagulation system during coronary artery bypass grafting: Com-
parison between on-pump and off-pump techniques. J Thorac 
Cardiovasc Surg, 2006; 131: 290–297.
 8.  Englberger L, Immer FF, Eckstein FS, Berdat PA, Haeberli A, 
Carrel TP. Off-pump coronary artery bypass operation does not 
increase procoagulant and fibrinolytic activity: Preliminary re-
sults. Ann Thorac Surg, 2004; 77: 1560–1566.
 9.  Raja SG, Dreyfus GD. Impact of off-pump coronary artery 
bypass surgery on postoperative bleeding: Current best available 
evidence. J Card Surg, 2006; 21: 35–41.
 10.  White RH, Keenan CR. Effects of race and ethnicity on the inciden-
ce of venous thromboembolism. Thromb Res, 2009; 123: S11–S17.
 11.  Cohen AT, Tapson VF, Bergmann JF et al. Venous thrombo-
embolism risk and prophylaxis in the acute hospital care setting 
(ENDORSE study): A multinational cross-sectional study. Lancet, 
2008; 371: 387–394.
 12.  Geerts WH, Pineo GF, Heit JA et al. Prevention of venous throm-
boembolism: the Seventh ACCP Conference on Antithrombotic 
and Thrombolytic Therapy. Chest, 2004; 126: 338S–400S.
 13.  Goldhaber SZ, Tapson VF. A prospective registry of 5,451 pa-
tients with ultrasoundconfirmed deep vein thrombosis. Am 
J Cardiol, 2004; 93: 259–262.
 14.  Mattos MA, Londrey GL, Leutz DW et al. Color-flow duplex 
scanning for the surveillance and diagnosis of acute deep venous 
thrombosis. J Vasc Surg, 1992; 15: 366–375.
 15.  Josa M, Siouffi SY, Silverman AB, Barsamian EM, Khuri SF, 
Sharma GV. Pulmonary embolism after cardiac surgery. J Am Coll 
Cardiol, 1993; 21: 990–996.
 16.  Shammas NW. Pulmonary embolus after coronary artery bypass 
surgery: A review of the literature. Clin Cardiol, 2000; 23: 637–644.
 17.  Goldhaber SZ, Hirsch DR, MacDougall RC, Polak JF, Creager MA, 
Cohn LH. Prevention of venous thrombosis after coronary artery 
bypass surgery (a randomized trial comparing two mechanical 
prophylaxis strategies). Am J Cardiol, 1995; 76: 993–996.
 18.  Tapson VF, Decousus H, Pini M et al. Venous thromboembolism 
prophylaxis in acutely ill hospitalized medical patients: Findings 
from the International Medical Prevention Registry on Venous 
Thromboembolism. Chest, 2007; 132: 936–945.
 19.  Mismetti P, Laporte-Simitsidis S, Tardy B et al. Prevention of ve-
nous thromboembolism in internal medicine with unfractionated 
or low-molecularweight heparins: A meta-analysis of randomized 
clinical trials. Thromb Haemost, 2000; 83: 14–19.
 20.  Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. 
Meta-analysis of low molecular weight heparin in the prevention 
of venous thromboembolism in general surgery. Br J Surg, 2001; 
88: 913–930.
 21.  Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in 
the prevention and treatment of venous thromboembolism. 
J Thromb Haemost, 2006; 4: 1470–1475.
 22.  Chung TL, Pumplin DW, Holton LH 3rd, Taylor JA, Rodriguez ED, 
Silverman RP. Prevention of microsurgical anastomotic throm-
bosis using aspirin, heparin, and the glycoprotein IIb/IIIa in-
hibitor tirofiban. Plast Reconstr Surg, 2007; 120: 1281–1288.
 23.  Liau JV, Ferrandis R, López Forte C. Antiplatelet agents and an-
ticoagulants: Management of the anticoagulated surgical patient. 
Cir Esp, 2009; 85: 7–14.
 24.  Sirvinskas E, Veikutiene A, Grybauskas P et al. Influence of 
aspirin or heparin on platelet function and postoperative blood loss 
after coronary artery bypass surgery. Perfusion, 2006; 21: 61–66.
 25.  Veikutiene A, Sirvinskas E, Grybauskas P, Cimbolaityte J, Mon-
girdiene A, Veikutis V. Influence of preoperative treatment with 
aspirin or heparin on platelet function and intensity of posto-
perative bleeding in early period after coronary artery bypass 
surgery. Medicina (Kaunas), 2005; 41: 577–583.
 26.  Zibaeenezhad MJ, Mazloum Y. Heparin infusion after successful 
percutaneous coronary intervention: A prospective, randomized 
trial. Acta Cardiol, 2009; 64: 65–70.
 27. Ambrosetti M, Salerno M, Zambelli M, Mastropasqua F, 
Tramarin R, Pedretti RF. Deep vein thrombosis among patients 
entering cardiac rehabilitation after coronary artery bypass surgery. 
Chest, 2004; 125: 191–196.
 28.  Kearon C, Julian JA, Newman T, Ginsberg JS. Noninvasive diagno-
sis of deep vein thrombosis. Ann Intern Med, 1998; 128: 663–677.
 29.  Tapson VF, Caroll BA, Davi dson BL et al. The diagnostic appro-
ach to acute venous thromboembolism. Clinical practice guide-
line. American Thoracic Society. Am J Respir Crit Care Med, 
1999; 160: 1043–1066.
